Effectiveness of soil erosion barriers to reduce sediment connectivity at small basin scale in a fire-affected forest.

Forest fires and post-fire management practices (PFMP) cause changes in the hydrological response of a hillslope. This study evaluates the effect of log erosion barriers (LB) and Easy-Barriers® (EB) on the spatial patterns and values of structural sediment connectivity (SC) in a Mediterranean mountainous pine forest affected by an arson fire in August 2017. A drone flight was done in July 2019 (23 months after the fire and 11 months after the PFMP) to obtain a high-resolution orthomosaic and DEM (at 0.05 m). Two contrasted areas, with and without PFMP, were selected along the same hillslope and 26 small basins were identified: 16 in the treated area (mean area, slope and vegetation recovery of 916 m2, 60% and 25%; with 94 LB and 39 EB) and 10 in the untreated area (1952 m2, 75% and 20%). The aggregated index of sediment connectivity (AIC) was chosen to compute SC in three temporal scenarios: Before and just after the fire and when all PFMP were implemented including the incipient vegetation recovery. Output normalization allowed the comparison of the non-nested basins among them. After accounting the intrinsic differences among the basins and areas, and the temporal changes of SC between the three scenarios, the contribution of the barriers was estimated in 27% from the total decrease of SC in the treated area (-8.5%). The remaining 73% was explained by the vegetation recovery. The effectiveness of the LB (11.3% on average) and EB (13.4%) did not diminish with increasing slope gradients. These percentages become relevant considering the small area affected by the LB (2.8%) and EB (1.3%). Independent metrics (convergence index, flow width, flat areas and LS factor) also reported clear differences between the two areas -higher soil erosive intensity in the untreated area- and in accordance with the AIC results.

Assessment of residential environmental exposure to pesticides from agricultural fields in the Netherlands.

We developed a spatio-temporal model for the Netherlands to estimate environmental exposure to individual agricultural pesticides at the residential address for application in a national case-control study on Parkinson's disease (PD). Data on agricultural land use and pesticide use were combined to estimate environmental exposure to pesticides for the period 1961 onwards. Distance categories of 0-50 m, >50-100 m, >100-500 m and >500-1000 m around residences were considered. For illustration purposes, exposure was estimated for the control population (n=607) in the PD case-control study. In a small validation effort, model estimates were compared with pesticide measurements in air and precipitation collected at 17 stations in 2000-2001. Estimated exposure prevalence was higher for pesticides used on commonly cultivated (rotating) crops than for pesticides used on fruit and bulbs only. Prevalence increased with increasing distance considered. Moderate-to-high correlations were observed between model estimates (>100-500 m and >500-1000 m) and environmental pesticide concentrations measured in 2000-2001. Environmental exposure to individual pesticides can be estimated using relevant spatial and temporal data sets on agricultural land use and pesticide use. Our approach seems to result in accurate estimates of average environmental exposure, although it remains to be investigated to what extent this reflect personal exposure to agricultural pesticides.

Somatostatin receptor based hybrid imaging in sarcoidosis.

Several diagnostic imaging methodologies are available for the clinical evaluation of sarcoidosis, but all have their limitations. FDG PET/CT is frequently used, but this technique does not provide optimal results in all cases. Novel radiopharmaceuticals aimed at other disease targets may be helpful, particularly in cardiac sarcoidosis when FDG PET/CT has a low diagnostic accuracy, due to difficulties in preparing the patients who should use a specific diet combined with prolonged fasting. 68Ga-labeled somatostatin based receptor hybrid imaging is a potential alternative to FDG PET/CT. This short communication provides a rapid overview of initial findings concerning the application of 68Ga-labeled somatostatin based receptor hybrid imaging in the diagnosis of (cardiac) sarcoidosis activity.

Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer.

BACKGROUND: The distribution of promoter methylation throughout the lungs of patients with non-small cell lung cancer (NSCLC) is unknown. In this explorative study, we assessed the methylation status of the promoter region of 11 genes in brush samples of 3 well-defined endobronchial locations in patients with NSCLC and in brushes of former and current smokers without NSCLC. MATERIALS AND METHODS: The methylation status of RASSF1A, GATA4, GATA5, SFRP1, RARbeta2, DAPK, MGMT, p16, p14, CHFR and APC2 was determined in all samples using real-time methylation-specific PCR. RESULTS: Ten patients with NSCLC and 18 non-NSCLC controls were included. Eight patients had one or more methylated genes in their tumor brush. Promoter methylation of genes in proximal or contralateral locations was much less frequent than in tumor brushes, and almost exclusively occurred in normal tissue if the same gene was also methylated in the tumor brush. CONCLUSION: Promoter methylation almost exclusively occurred in tumor cells of patients with NSCLC.

Analysis of cytological specimens from mediastinal lesions obtained by endoscopic ultrasound-guided fine-needle aspiration.

BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) seems to be a powerful tool to obtain cytologic specimens from mediastinal and celiac lymph nodes, enlarged left adrenal glands, and intrapulmonary tumors with mediastinal extension. The diagnostic yield of EUS-FNA and the accuracy of cytologic specimens was evaluated. METHODS: Cytologic assessment of EUS-FNA specimens was performed and specimens were classified as positive, negative, suspicious for malignancy, or unsatisfactory for diagnosis. Cytology was compared with histologic and clinical (> or = 6 months) follow-up. RESULTS: Cytologic specimens were collected from 155 lymph nodes, 10 left adrenal glands, and 9 intrapulmonary tumor masses. For lymph nodes, the diagnostic yield was 0.65. After exclusion of unsatisfactory specimens, sensitivity, specificity, accuracy, and positive (PPV) and negative (NPV) predictive values of cytologic specimens were 0.92, 1.00, 0.93, 1.00, and 0.63, respectively. Subgroup analysis of lymph nodes with a dimension of > or = 10 mm showed similar results. With EUS imaging only, lymph node diameter and a round or irregular shape were significant predictors of malignancy at multiple logistic regression analysis, but their clinical usefulness is very limited (PPV = 0.78 and NPV = 0.45). For left adrenal gland specimens, sensitivity and specificity were 0.89 and 1.00, respectively. From intrapulmonary masses, 8 true-positive and 1 true-negative specimens were obtained. CONCLUSIONS: Cytologic specimens from mediastinal or celiac lymph nodes obtained with EUS-FNA were reliable and accurate. Specimens from left adrenal glands and intrapulmonary tumor masses showed promising results.

The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases.

UNLABELLED: Positron emission tomography (PET) is more accurate than computed tomography (CT) in the staging of non-small cell lung cancer (NSCLC). We analyzed the prognostic value of PET for survival in NSCLC patients. METHODS: Consecutive patients with proven NSCLC with PET for staging were selected. Staging by laboratory tests, bronchoscopy, chest X-ray, and CT was performed in all patients, leading to a clinical stage (c-TNM) prior to PET. A separate classification (pet-TNM) was obtained from PET images by observers blinded to clinical data. We performed univariate survival analysis with ECOG performance score, sex, weight loss, comorbidity, histology, c-TNM, and pet-TNM as variables. Cox regression analysis was performed with significant variables from the univariate analyses. RESULTS: Two hundred and sixty-six patients were included, 205 men and 61 women. c-TNM and pet-TNM were identical in 150 (56%) patients, 69 were upstaged, and 47 were downstaged by PET. At time of analysis, 198 (74%) patients had died. Univariate analysis showed significant survival differences for ECOG performance score (0 versus 1/2), weight loss (<10% versus >or=10%), pulmonary comorbidity, c-TNM, and pet-TNM (stage IA versus IB, IIA, IIB, IIIA, IIIB, IV). Cox regression analysis identified pet-TNM as the most significant (p < 0.001) prognostic factor, followed by ECOG performance score (p = 0.018). CONCLUSION: Tumor stage as determined by PET is the most significant prognostic factor for survival in patients with NSCLC.

Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.

PURPOSE: We investigated whether application of positron emission tomography (PET) immediately after first presentation might simplify staging while maintaining accuracy, as compared with traditional strategy in routine clinical setting. METHODS: At first presentation, patients with a provisional diagnosis of lung cancer without overt dissemination were randomly assigned to traditional work-up (TWU) according to international guidelines or early PET followed by histologic/cytologic verification of lesions, or imaging and follow-up. Patients with [18F] fluorodeoxyglucose (18FDG) -avid, noncentral tumors without suspicion of mediastinal or distant metastases on PET proceeded directly to thoracotomy. Follow-up in presumed benign lesions was at least 12 months. In patients treated with surgery or neoadjuvant therapy, the quality of staging was measured by comparing the clinical stage to the final stage (combination of peroperative staging and 6 months of follow-up). To investigate test substitution, we analyzed the number of (non)invasive tests to achieve clinical TNM staging, and its associated costs. RESULTS: Between 1999 and 2001, 465 patients (233 TWU, 232 PET) were enrolled at 22 hospitals. The mean (standard deviation) number of procedures to finalize staging was equal in the TWU arm and the PET arm: 7.9 (2.0) v 7.9 (1.9), P = .90, respectively. Mediastinoscopies occurred significantly less often in the PET arm. Agreement between clinical and final stage was good in both arms (kappa = .85 v .78; P = .07). Costs did not differ significantly. CONCLUSION: Up-front 18FDG-PET in patients with (suspected) lung cancer does not reduce the overall number of diagnostic test, but it maintains quality of TNM staging with the use of less invasive surgery.

Diagnosis of mediastinal and left adrenal abnormalities with endoscopic ultrasonography.

Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) is increasingly used for sampling of mediastinal or left adrenal abnormalities. We report two patients in whom EUS-FNA led to the diagnosis of malignancy. In one patient, left adrenal metastasis of a rectal adenocarcinoma was diagnosed, while in the other patient EUS-FNA established a plasmocytoma in the right hilum and mediastinum after several non-diagnostic interventions.

Technical description of endoscopic ultrasonography with fine-needle aspiration for the staging of lung cancer.

BACKGROUND: Endoscopic ultrasonography (EUS) is a novel method for staging of the mediastinum in lung cancer patients. The recent development of linear scanners enables safe and accurate fine-needle aspiration (FNA) of mediastinal and upper abdominal structures under real-time ultrasound guidance. However, various methods and equipment for mediastinal EUS-FNA are being used throughout the world, and a detailed description of the procedures is lacking. A thorough description of linear EUS-FNA is needed. METHODS: A step-by-step description of the linear EUS-FNA procedure as performed in our hospital will be provided. Ultrasonographic landmarks will be shown on images. The procedure will be related to published literature, with a systematic literature search. RESULTS: EUS-FNA is an outpatient procedure under conscious sedation. The typical linear EUS-FNA procedure starts with examination of the retroperitoneal area. After this, systematic scanning of the mediastinum is performed at intervals of 1-2cm. Abnormalities are noted, and FNA of the abnormalities can be performed. Specimens are assessed for cellularity on-site. The entire procedure takes 45-60 min. CONCLUSIONS: EUS-FNA is minimally invasive, accurate, and fast. Anatomical areas can be reached that are inaccessible for cervical mediastinoscopy. EUS-FNA is useful for the staging of lung cancer or the assessment and diagnosis of abnormalities in the posterior mediastinum.

PET for the evaluation of pleural thickening observed on CT.

UNLABELLED: Early discrimination between benign and malignant pleural diseases is vital for the treatment and prognosis of a patient. Imaging is traditionally performed with CT or MRI, with an accuracy of 50%-75%. PET has proven to be superior as a diagnostic tool in several malignancies. In this prospective study, PET results in patients with pleural abnormalities on CT were compared with histologic results. METHODS: Eligible patients had pleural thickening on CT and were medically fit for surgical diagnostic procedures. All patients underwent PET. Qualitative assessment led to a PET score of 1 (definitely normal), 2 (probably normal), 3 (probably abnormal), or 4 (definitely abnormal). PET scores of 1 or 2 indicated a negative PET finding, whereas PET scores of 3 or 4 indicated a positive PET finding. Pathologic verification techniques included thoracocentesis, thoracoscopy, or open pleural biopsy at thoracotomy. RESULTS: Thirty-two patients were enrolled, 19 with malignant and 13 with benign pleural disease. PET was true positive in 18 and true negative in 12 patients, with an accuracy and negative predictive value of 94% and 92%, respectively. PET was false negative in a patient with a slowly growing malignant solitary fibrous tumor and false positive in a patient with infectious pleuritis. Median standardized uptake values calculated for 7 patients with malignant and benign pleural diseases were 6.28 and 1.69, respectively. Patients with a PET score of 1 or 2 survived significantly longer than patients with a PET score of 3 or 4. CONCLUSION: Qualitative assessment of pleural thickening with PET accurately discriminates between malignant and benign pleural thickening, with a high accuracy and negative predictive value.

Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer.

OBJECTIVE: To review the current concepts in the mediastinal staging of nonsmall cell lung cancer (NSCLC), evaluating traditional and modern staging modalities. SUMMARY BACKGROUND DATA: Staging of NSCLC includes the assessment of mediastinal lymph nodes. Traditionally, computed tomography (CT) and mediastinoscopy are used. Modern staging modalities include magnetic resonance imaging (MRI), positron emission tomography (PET), and endoscopic ultrasound with fine-needle aspiration (EUS-FNA) METHODS: Literature was searched with PubMed and SUMSearch for original, peer-reviewed, full-length articles. Studies were evaluated on inclusion criteria, sample size, and operating characteristics. Endpoints were accuracy, safety, and applicability of the staging methods. RESULTS: CT had moderate sensitivities and specificities. With few exceptions magnetic resonance imaging (MRI) offered no advantages when compared with CT, against higher costs. PET was significantly more accurate than CT. Mediastinoscopy and its variants were widely used as gold standard, although meta-analyses were absent. Percutaneous transthoracic needle biopsy (PTNB) and transbronchial needle biopsy (TBNA) were moderately sensitive and specific. EUS-FNA had high sensitivity and specificity, is a safe and fast procedure, and is cost-effective. EUS-FNA evaluates largely a nonoverlapping mediastinal area compared with mediastinoscopy. CONCLUSIONS: PET has the highest accuracy in the mediastinal staging of NSCLC, but is not generally used yet. EUS-FNA has the potential to perform mediastinal tissue sampling more accurate than TBNA, PTNB, and mediastinoscopy, with fewer complications and costs. Although promising, EUS-FNA is still experimental. Mediastinoscopy is still considered as gold standard for mediastinal staging of NSCLC.